| scholarly article | Q13442814 |
| P2093 | author name string | Mark K Ferguson | |
| Hai-Yan Liu | |||
| Yonglin Pu | |||
| Stephanie Y Jo | |||
| Joshua H Finkle | |||
| Chenpeng Zhang | |||
| Cindy Yuan | |||
| Xuee Zhu | |||
| P2860 | cites work | Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. | Q50909685 |
| Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. | Q51005942 | ||
| A gradient-based method for segmenting FDG-PET images: methodology and validation. | Q51026384 | ||
| Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer. | Q51602164 | ||
| A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. | Q52377234 | ||
| Quantification of metabolic tumor activity and burden in patients with non-small-cell lung cancer: Is manual adjustment of semiautomatic gradient-based measurements necessary? | Q53014495 | ||
| FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma. | Q53089675 | ||
| Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy. | Q53140054 | ||
| The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. | Q53229977 | ||
| A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. | Q53515309 | ||
| The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer | Q57272532 | ||
| Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805 | Q71961890 | ||
| Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer | Q73181790 | ||
| Revisions in the International System for Staging Lung Cancer | Q28241070 | ||
| Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging | Q31159102 | ||
| Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer | Q33498589 | ||
| Metabolic Tumor Volume Measured by F-18 FDG PET/CT can Further Stratify the Prognosis of Patients with Stage IV Non-Small Cell Lung Cancer | Q33704656 | ||
| Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. | Q35268628 | ||
| Pretreatment FDG-PET metrics in stage III non-small cell lung cancer: ACRIN 6668/RTOG 0235. | Q35474006 | ||
| Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial | Q35532111 | ||
| Multidisciplinary management of lung cancer | Q35635254 | ||
| Cutpoint selection for discretizing a continuous covariate for generalized estimating equations. | Q35983616 | ||
| Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times | Q36304366 | ||
| Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. | Q36495076 | ||
| Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). | Q36943220 | ||
| Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition). | Q36943225 | ||
| Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. | Q37186376 | ||
| What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom | Q37424511 | ||
| Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer | Q38014317 | ||
| Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer | Q38018229 | ||
| Treatment of lung cancer | Q38043169 | ||
| Performance of whole-body PET/CT for the detection of distant malignancies in various cancers: a systematic review and meta-analysis | Q38052815 | ||
| Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value | Q38136865 | ||
| Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis | Q38246442 | ||
| Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib | Q38895657 | ||
| Metabolic tumor volume predicts overall survival and local control in patients with stage III non-small cell lung cancer treated in ACRIN 6668/RTOG 0235. | Q39373649 | ||
| The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours | Q39512984 | ||
| RT_Image: an open-source tool for investigating PET in radiation oncology | Q42615272 | ||
| FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy. | Q43933738 | ||
| Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen | Q45022936 | ||
| Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. | Q45130086 | ||
| The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. | Q46373510 | ||
| Positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced nonsmall cell lung cancer--initial results | Q46634592 | ||
| Lung Cancer Staging Essentials: The New TNM Staging System and Potential Imaging Pitfalls | Q46948530 | ||
| The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer | Q49014865 | ||
| Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. | Q49058675 | ||
| Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. | Q50690978 | ||
| P433 | issue | 8 | |
| P304 | page(s) | 1275-1284 | |
| P577 | publication date | 2017-03-07 | |
| P1433 | published in | European Journal of Nuclear Medicine and Molecular Imaging | Q15708890 |
| P1476 | title | Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer | |
| P478 | volume | 44 |
| Q64073259 | Q64073259 |
| Q89037037 | Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging |
| Q58594704 | Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer |
Search more.